300 results found.

Head and Neck Cancer, or Colon Cancer Clinical Trial using Head and neck; Colon

Brown University - Recruiting 18 years or older.
- A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study.
Head and neck; Colon

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Onc Clinical Trial using AMG 232

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors.
AMG 232

Renal Cell Carcinoma Clinical Trial using everolimus and bevacizumab

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC).
everolimus and bevacizumab

Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma.
Sorafenib (Nexavar, BAY43-9006)

Advanced Cancers Clinical Trial using Lorazepam; Placebo; Haloperidol decanoate; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit.
Lorazepam; Placebo; Haloperidol decanoate; Questionnaires

Colorectal Cancer Clinical Trial using panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Northwestern University - Recruiting 18 years or older.
- A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer.
panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Ovarian Cancer Clinical Trial using IMAB027

Ganymed Pharmaceuticals AG - Recruiting 18 years or older.
- A First-in-human Dose Escalation and Dose Finding Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR).
IMAB027

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
BI 853520

Head and Neck Neoplasms Clinical Trial using Placebo; Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Placebo; Afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Non-small Cell Lung Cancer Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer.
MK-3475

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours.
BI 853520

Advanced Cancer Clinical Trial using Dasatinib; Bevacizumab; Paclitaxel

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel in Patients With Advanced Malignancies.
Dasatinib; Bevacizumab; Paclitaxel

Non-Small Cell Lung Cancer, Anemia, Cancer, or Lung Cancer Clinical Trial using darbepoetin alfa 500 mcg Q3W; placebo

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
darbepoetin alfa 500 mcg Q3W; placebo

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit.
BI 836845

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Japan Breast Cancer Research Group - Recruiting 20 years to 75 years.
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-.
Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Carcinoma, or Lymphoma Clinical Trial using rh IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers.
rh IL-15

Cancer, or Solid Tumor Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors.
MK-3475

Hepatic Complications, Liver Metastases, or Unspecified Adult Sol Clinical Trial using trametinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
trametinib; pharmacological study; laboratory biomarker analysis

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Non-Small Cell Lung Cancer Clinical Trial using onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Genentech - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease.
onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Endometrial Cancer Clinical Trial using AEZS-108 / zoptarelin doxorubicin; doxorubicin

AEterna Zentaris - Recruiting 18 years or older.
- Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer..
AEZS-108 / zoptarelin doxorubicin; doxorubicin

Breast Cancer Clinical Trial using GDC-0941; placebo; fulvestrant; GDC-0980

Genentech - Recruiting 18 years or older.
- A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy.
GDC-0941; placebo; fulvestrant; GDC-0980

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
MPDL3280A

Breast Cancer Clinical Trial using GDC-0032; Docetaxel; Paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
GDC-0032; Docetaxel; Paclitaxel

Gastric Cancer Clinical Trial using GDC-0068; Placebo; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
GDC-0068; Placebo; mFOLFOX6

Non-Small Cell Lung Cancer Clinical Trial using GDC-0941; carboplatin; paclitaxel; bevacizumab; Placebo

Genentech - Recruiting 18 years or older.
- A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer.
GDC-0941; carboplatin; paclitaxel; bevacizumab; Placebo

HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junc Clinical Trial using MM-111; Paclitaxel; Trastuzumab

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.
MM-111; Paclitaxel; Trastuzumab

Advanced Cancer Clinical Trial using crizotinib

Pfizer - Recruiting 18 years or older.
- A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients.
crizotinib

Advanced Cancer Clinical Trial using Questionnaire; Actigraph

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients.
Questionnaire; Actigraph

Advanced Cancer Clinical Trial using LY2835219; Fulvestrant

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer.
LY2835219; Fulvestrant

Epithelial Cancer Clinical Trial using Lapatinib; Radiation therapy

Virginia Commonwealth University - Recruiting 18 years or older.
- A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease.
Lapatinib; Radiation therapy

Breast Cancer Clinical Trial using Paclitaxel; BKM120 matching placebo; BKM120

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation..
Paclitaxel; BKM120 matching placebo; BKM120

Non-small Cell Lung Carcinoma Clinical Trial using chemotherapy

Yonsei University - Recruiting 18 years or older.
- .
chemotherapy

Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Clinical Trial using oxaliplatin; irinotecan hydrochloride; leucovorin calcium; fluorouracil; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies.
oxaliplatin; irinotecan hydrochloride; leucovorin calcium; fluorouracil; laboratory biomarker analysis

Metastatic Advanced Gastric Cancer Clinical Trial using Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Yonsei University - Recruiting 20 years or older.
- .
Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Advanced Cancer, Metastatic Cancer, Lymphoma, Metastatic Breast C Clinical Trial using LY3023414; Midazolam; Letrozole

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer.
LY3023414; Midazolam; Letrozole

Malignant Neoplasm Clinical Trial using fluorine F 18 d-FMAU; positron emission tomography; computed tomography

University of Southern California - Recruiting 19 years or older.
- 18F-FMAU for Imaging in Cancer Patients.
fluorine F 18 d-FMAU; positron emission tomography; computed tomography

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY.
MPDL3280A; docetaxel

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
MPDL3280A

Gastric Cancer Clinical Trial using Olaparib; Paclitaxel; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy.
Olaparib; Paclitaxel; Placebo

Solid Tumors, Melanoma, or Metastatic Colorectal Cancer Clinical Trial using CEP-32496

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2.
CEP-32496

Metastatic GPNMB Over-expressing Triple Negative Breast Cancer Clinical Trial using CDX-011; Capecitabine

Celldex Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study).
CDX-011; Capecitabine

Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Clinical Trial using Olaparib 300mg tablets

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy..
Olaparib 300mg tablets

Neoplasms Clinical Trial using Paclitaxel; Copanlisib (BAY80-6946)

Bayer - Recruiting 18 years or older.
- A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy.
Paclitaxel; Copanlisib (BAY80-6946)

Uveal Melanoma Clinical Trial using RAD001 (Everolimus) and Pasireotide (SOM230) LAR

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma.
RAD001 (Everolimus) and Pasireotide (SOM230) LAR

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Advanced Cancer Clinical Trial using Doxil; Bevacizumab; Temsirolimus

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- A Phase I Trial of Doxil, Bevacizumab and Temsirolimus.
Doxil; Bevacizumab; Temsirolimus

Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Ca Clinical Trial using cisplatin; paclitaxel; carboplatin; brachytherapy

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
cisplatin; paclitaxel; carboplatin; brachytherapy

Ovarian Stromal Cancer Clinical Trial using paclitaxel; carboplatin; bleomycin sulfate; etoposide phosphate; cisplatin

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary.
paclitaxel; carboplatin; bleomycin sulfate; etoposide phosphate; cisplatin

Esophageal Cancer, or Gastric Cancer Clinical Trial using Afatinib (BIBW 2992)

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer.
Afatinib (BIBW 2992)

Rectal Cancer Clinical Trial using Advanced MR Imaging

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer.
Advanced MR Imaging

Advanced Cancers Clinical Trial using Vandetanib; Everolimus

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer.
Vandetanib; Everolimus

Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, or Locall Clinical Trial using FOLFIRINOX; Algenpantucel-L Immunotherapy; 5-FU Chemoradiation; Gemcitabine; Capecitabine; Nab-Paclitaxel

NewLink Genetics Corporation - Recruiting 18 years or older.
- A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcuter-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
FOLFIRINOX; Algenpantucel-L Immunotherapy; 5-FU Chemoradiation; Gemcitabine; Capecitabine; Nab-Paclitaxel

Non Small Cell Lung Cancer, ROS1 Proto Oncogene, or Crizotinib Clinical Trial using Crizotinib

OxOnc Development LP - Recruiting 18 years or older.
- Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus.
Crizotinib

Differentiated Thyroid Cancer Clinical Trial using vandetanib; placebo

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy..
vandetanib; placebo

Non-Small Cell Lung Cancer Clinical Trial using Cabozantinib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
Cabozantinib

Hematological Malignancies Clinical Trial using KPT-330

NPM Pharma Inc. - Recruiting 18 years or older.
- A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Malignancies.
KPT-330

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using laboratory biomarker analysis; lymphadenectomy

Gynecologic Oncology Group - Recruiting 18 years or older.
- Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4 CM, IIB to IVA) Undergoing Pelvic and Para-Aortic (Abdominal) Lymphadenectomy.
laboratory biomarker analysis; lymphadenectomy

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors..
PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Advanced Cancer Clinical Trial using LY2874455

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer..
LY2874455

Pancreatic Cancer Clinical Trial using 24 Gy in 3 fractions

UMC Utrecht - Recruiting 18 years or older.
- Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer.
24 Gy in 3 fractions

Breast Cancer Clinical Trial using MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer.
MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide

Advanced Solid Tumors (Excluding Breast Cancer) Clinical Trial using TAS-102 tablets; TAS-102 oral solution

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI.
TAS-102 tablets; TAS-102 oral solution

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using yttrium Y 90 glass microspheres; laboratory biomarker analysis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Humanitarian Device Exemption Treatment Protocol of TheraSpherer For Treatment of Unresectable Hepatocellular Carcinoma.
yttrium Y 90 glass microspheres; laboratory biomarker analysis

Breast Cancer Clinical Trial using pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer..
pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Neoplasms Clinical Trial using Vemurafenib; Cobimetinib; Onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES.
Vemurafenib; Cobimetinib; Onartuzumab

Gastric Cancer Clinical Trial using trastuzumab emtansine; taxane

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction.
trastuzumab emtansine; taxane

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of First-line Maintenance Tarceva vs Tarceva at the Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-based Chemotherapy.
erlotinib [Tarceva]; Placebo

Breast Cancer Clinical Trial using Kadcyla (trastuzumab emtansine)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment..
Kadcyla (trastuzumab emtansine)

ALK Positive Non Small Cell Lung Cancer Clinical Trial using PF-06463922

Pfizer - Recruiting 18 years or older.
- Phase 1/2 Study Of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations.
PF-06463922

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cance Clinical Trial using AUY922; BYL719

Novartis - Recruiting 18 years or older.
- A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
AUY922; BYL719

Squamous Cell Carcinoma, or Head and Neck Cancer Clinical Trial using EGFR Antisense DNA

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- Safety and Efficacy of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
EGFR Antisense DNA

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Advanced Cancer Clinical Trial using Nab-paclitaxel; Bevacizumab; Gemcitabine

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies.
Nab-paclitaxel; Bevacizumab; Gemcitabine

Advanced Cancers Clinical Trial using Oxaliplatin; Capecitabine; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.
Oxaliplatin; Capecitabine; Bevacizumab

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Lung Cancer Clinical Trial using panitumumab; carboplatin; paclitaxel

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy +/- Cetuximab in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10).
panitumumab; carboplatin; paclitaxel

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors.
calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Met Clinical Trial using L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

Philogen S.p.A. - Recruiting 18 years to 70 years.
- Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

Advanced Gastric Cancer Clinical Trial using taxel plus raltitrexed; taxol

Fudan University - Recruiting 18 years to 75 years.
- Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies.
taxel plus raltitrexed; taxol

Carcinoma, Squamous Cell of Head and Neck Clinical Trial using Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36).
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Metastatic Breast Cancer Clinical Trial using Fulvestrant; Goserelin; Anastrozole

Hospital Affiliated to Military Medical Science, Beijing - Recruiting 18 years to 60 years.
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer.
Fulvestrant; Goserelin; Anastrozole

Adult Primary Hepatocellular Carcinoma, Adult Primary Undifferent Clinical Trial using sorafenib tosylate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting N/A or older.
- Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC.
sorafenib tosylate; laboratory biomarker analysis

Solid Tumors, or Metastatic Disease Clinical Trial using Histological biopsy procedure

UMC Utrecht - Recruiting 18 years or older.
- Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection).
Histological biopsy procedure

Hormone Receptor Positive Breast Cancer Clinical Trial using faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy..
faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Biliary Cancer Clinical Trial using SPI-1620 & Docetaxel

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer.
SPI-1620 & Docetaxel

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Advanced Cancer Clinical Trial using Sirolimus; Cetuximab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies.
Sirolimus; Cetuximab

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using eribulin mesylate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.
eribulin mesylate; laboratory biomarker analysis; pharmacological study

Head and Neck Squamous Cell Carcinoma Clinical Trial using Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Paclitaxel; Carboplatin; Cetuximab; Docetaxel; Cisplatin; Fluorouracil; Radiotherapy (RT); Chemotherapy

Thymoma, Thymic Carcinoma, or Clinical Masaoka Stage II-IVA Clinical Trial using Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma.
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Delirium, or Advanced Cancer Clinical Trial using Olanzapine; Haloperidol

VU University Medical Center - Recruiting 18 years or older.
- Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer.
Olanzapine; Haloperidol

Cancer, or Advanced Solid Tumors Clinical Trial using Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

VU University Medical Center - Recruiting 18 years or older.
- Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies..
Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

Advanced Lung Cancer Clinical Trial using Ganetespib (STA-9090) and crizotinib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers.
Ganetespib (STA-9090) and crizotinib

Renal Cell Cancer Clinical Trial

VU University Medical Center - Recruiting 18 years or older.
- Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients.

Head and Neck Cancer Clinical Trial using LUZ11

Luzitin SA - Recruiting 18 years or older.
- An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer.
LUZ11

Solid Tumor, or Non-small Cell Lung Cancer Clinical Trial using MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer.
MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Colorectal Cancer, Liver Metastasis, or Colorectal Adenocarcinoma Clinical Trial using Sulindac; Placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer.
Sulindac; Placebo

Non-small Cell Lung Cancer Metastatic Clinical Trial using carboplatin; paclitaxel; ABP 215; bevacizumab

Amgen - Recruiting 18 years to 80 years.
- A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer.
carboplatin; paclitaxel; ABP 215; bevacizumab

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Brea Clinical Trial using BMN 673

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations.
BMN 673

Histologically or Cytologically Confirmed Pancreatic Ca, or Unres Clinical Trial using Gemcitabine; Intra Arterial Catheterization and Embolization; Indwelling Intraarterial Catheter

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial.
Gemcitabine; Intra Arterial Catheterization and Embolization; Indwelling Intraarterial Catheter

Advanced Metastatic Breast Cancer Clinical Trial using AZD2014; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
AZD2014; Fulvestrant

Advanced Gastrointestinal Cancer Clinical Trial using single pilot interview; goals-of-care (GOC) video; goals-of-care (GOC) video and narrative question; usual care

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients.
single pilot interview; goals-of-care (GOC) video; goals-of-care (GOC) video and narrative question; usual care

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Renal Cell Carcinoma Clinical Trial using Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma.
Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

Prostatic Neoplasms Clinical Trial using Cabozantinib; Docetaxel; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
Cabozantinib; Docetaxel; Prednisone

Neoplasms Clinical Trial using Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors.
Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

Local Advanced or Metastatic Postmenopausal Breast Cancer Clinical Trial

AstraZeneca - Recruiting N/A or older.
- LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer.

Ovarian Neoplasms, Peritoneal Neoplasms, or Fallopian Tube Neopla Clinical Trial using Trabectedin; DOXIL; Dexamethasone

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Trabectedin; DOXIL; Dexamethasone

Terminally Ill, Histologically-confirmed Advanced Cancer, or Intr Clinical Trial using Substance P-Saporin

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain.
Substance P-Saporin

Advanced Cancers Clinical Trial using Crizotinib (Xalkori); Pazopanib; Pemetrexed

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies.
Crizotinib (Xalkori); Pazopanib; Pemetrexed

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Reolysin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer.
Paclitaxel; Reolysin

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Breast Neoplasms, or Breast Cancer Clinical Trial using Taxane; Taxotere; Abraxane; Ixabepilone

The Methodist Hospital System - Recruiting 18 years or older.
- Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy..
Taxane; Taxotere; Abraxane; Ixabepilone

Indolent B-cell Lymphoma, or Chronic Lymphocytic Leukaemia Clinical Trial using DI-B4

Cancer Research UK - Recruiting 18 years or older.
- A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies.
DI-B4

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673; Physician's-Choice

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease.
BMN 673; Physician's-Choice

Non Small Cell Lung Cancer Clinical Trial using Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy..
Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

Hepatocellular Carcinoma Clinical Trial using Sorafenib; Doxorubicin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib.
Sorafenib; Doxorubicin

Breast Cancer Clinical Trial using Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer.
Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 65 years or older.
- Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice..

Solid Tumors, or Advanced Cancer Clinical Trial using Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance.
Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

Cancer, or Quality of Life Clinical Trial using self-completion questionnaire

Hospices Civils de Lyon - Recruiting 18 years or older.
- Preliminary Study of Financial Distress and Quality of Life in Patients With Advanced Cancer.
self-completion questionnaire

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Malignant Solid Tumour, or Gastroesophageal Cancer Clinical Trial using Tivantinib; FOLFOX

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II).
Tivantinib; FOLFOX

Pancreatic Carcinoma Non-resectable Clinical Trial using CyberKnifer Stereotactic Body Radiotherapy(SBRT)Boost

Ottawa Hospital Research Institute - Recruiting 19 years to 80 years.
- Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnifer Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer.
CyberKnifer Stereotactic Body Radiotherapy(SBRT)Boost

Head and Neck Cancer Clinical Trial using everolimus; laboratory biomarker analysis

Yonsei University - Recruiting 18 years or older.
- An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer.
everolimus; laboratory biomarker analysis

Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non Clinical Trial using AZD8186

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
AZD8186

Locally Advanced Breast Cancer Clinical Trial using Neoadjuvant Chemotherapy with Docetaxel

Yonsei University - Recruiting 20 years to 70 years.
- .
Neoadjuvant Chemotherapy with Docetaxel

Head and Neck Cancer, Oral Cavity Cancer, or Oropharyngeal Cancer Clinical Trial using Valproic Acid

Instituto do Cancer do Estado de Sao Paulo - Recruiting N/A to 65 years.
- Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Valproic Acid

Colorectal Cancer, or Adenoma Clinical Trial using Standard Colonoscopy; G-EYE(TM) Colonoscopy

Smart Medical Systems Ltd. - Recruiting 50 years or older.
- G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate - Randomized Tandem Study With Different Endoscopist.
Standard Colonoscopy; G-EYE(TM) Colonoscopy

Breast Cancer Metastatic Clinical Trial using PF-03084014; Docetaxel

Pfizer - Recruiting 18 years or older.
- Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer.
PF-03084014; Docetaxel

Advanced Non Small Cell Lung Cancer, or Advanced (Inoperable) Non Clinical Trial using AZD9291

AstraZeneca - Recruiting 18 years or older.
- Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent.
AZD9291

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinet Clinical Trial using AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies..
AZD5363

Advanced Solid Tumors, or Lymphomas Clinical Trial using Camptothecin-20-O-Propionate Hydrate (CZ48)

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Camptothecin-20-O-Propionate Hydrate (CZ48)

Cervical Cancer, Uterine Cancer, Vaginal Cancer, or Carcinoma of Clinical Trial using Image-guided brachytherapy

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO).
Image-guided brachytherapy

Fallopian Tube, Primary Peritoneal Cancer, or Solid Tumors (eg Br Clinical Trial using ABT-767

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ABT-767

Advanced Cancers Clinical Trial using Everolimus; Anakinra; Denosumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies.
Everolimus; Anakinra; Denosumab

Prostatic Neoplams, Prostate Cancer, Neoplasm, Prostate, or Neopl Clinical Trial using AMG 386; Abiraterone; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer.
AMG 386; Abiraterone; Prednisone

Stage IV Pancreatic Cancer Clinical Trial using Gemcitabine; nab-paclitaxel; FOLFIRINOX; Immunohistochemistry (IHC) Analysis; Metformin

Pancreatic Cancer Research Team - Recruiting 18 years or older.
- A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer.
Gemcitabine; nab-paclitaxel; FOLFIRINOX; Immunohistochemistry (IHC) Analysis; Metformin

Solid Tumors, or Hepatic Dysfunction Clinical Trial using Trametinib

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
Trametinib

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation.
BMN 673

Thymoma, or Thymus Neoplasms Clinical Trial using Sunitinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy.
Sunitinib

Colorectal Cancer Clinical Trial using PD-0332991, 5-FU, oxaliplatin

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of the CDK4/6 Inhibitor PD-0332991, 5-Fluorouracil, and Oxaliplatin in Patients With Advanced Refractory Colorectal Cancer.
PD-0332991, 5-FU, oxaliplatin

Locally Advanced Pancreatic Cancer and Have Started Treatment Wit Clinical Trial using Alecsat

CytoVac A/S - Recruiting 18 years or older.
- A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients.
Alecsat

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Gastric Cancer Clinical Trial using Rilotumumab; Placebo

Amgen - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Rilotumumab; Placebo

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Solid Tumors, Cancer, or NSCLC Clinical Trial using cabozantinib capsules; cabozantinib tablets

Exelixis - Recruiting 20 years or older.
- Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
cabozantinib capsules; cabozantinib tablets

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Unresectable Hepatocellular Carcinoma With Portal Vein Thrombosis Clinical Trial using TheraSphere; Sorafenib

BTG International Inc. - Recruiting 18 years or older.
- A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSpherer) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT).
TheraSphere; Sorafenib

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; taxane; anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER.
trastuzumab [Herceptin]; taxane; anthracycline

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Mesothelioma Clinical Trial using Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Toxicity Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma..
Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy

Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Desmo Clinical Trial using vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.
vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

Advanced Cancers Clinical Trial using Telephone Survey

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer.
Telephone Survey

Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Ca Clinical Trial using ipilimumab; gemcitabine hydrochloride; laboratory biomarker analysis

Northwestern University - Recruiting 18 years or older.
- Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study.
ipilimumab; gemcitabine hydrochloride; laboratory biomarker analysis

Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Lar Clinical Trial using PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).
PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

Carcinoma, Non-Small Cell Lung Clinical Trial using Radiation Therapy and EGFR-TKI target therapy

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer.
Radiation Therapy and EGFR-TKI target therapy

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer.
bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, or Unspecified Ad Clinical Trial using veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1 Trial of ABT-888 and SCH727965 Without or With Carboplatin in Patients With Advanced Solid Tumors.
veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using dabrafenib; pazopanib hydrochloride; Correlative studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors.
dabrafenib; pazopanib hydrochloride; Correlative studies

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using tivozanib; pharmacological study; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma.
tivozanib; pharmacological study; laboratory biomarker analysis

Squamous Cell Carcinomas Clinical Trial using Reduced Dose Radiation; Standard Dose Radiation

Mount Sinai School of Medicine - Recruiting 18 years or older.
- The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV16 Positive Oropharynx Cancer.
Reduced Dose Radiation; Standard Dose Radiation

Advanced Cancer Clinical Trial using Temsirolimus; Bevacizumab; Paclitaxel; Sorafenib; Carboplatin

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer.
Temsirolimus; Bevacizumab; Paclitaxel; Sorafenib; Carboplatin

Carcinoma, Non-Small-Cell Lung Clinical Trial using PF-02341066

Pfizer - Recruiting 18 years or older.
- Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene.
PF-02341066

Lymphoma, Non-Hodgkin Clinical Trial using PF-05082566; rituximab

Pfizer - Recruiting 18 years or older.
- A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL).
PF-05082566; rituximab

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Advanced Rectal Cancer Clinical Trial using Induction and gap chemotherapy (Capecitabine combine with oxaliplatin); standard chemoradiotherapy

Sun Yat-sen University - Recruiting 18 years to 70 years.
- Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Induction and gap chemotherapy (Capecitabine combine with oxaliplatin); standard chemoradiotherapy

Gastrointestinal Cancer Clinical Trial using Panitumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater.
Panitumumab

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Nasopharyngeal Carcinoma Clinical Trial using OPB-51602

National University Hospital, Singapore - Recruiting 21 years or older.
- The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal Carcinoma Followed By A Biomarker Study Evaluating OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy.
OPB-51602

Neoplasms Clinical Trial using BAY1082439

Bayer - Recruiting 21 years or older.
- An Open Label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1082439 Given Once Daily in Subjects With Advanced Malignancies.
BAY1082439

Advanced Stage Head and Neck Cancer Clinical Trial using Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- RECONSTRUCTIVE SURGERY For Head And Neck Cancer Patients: A Prospective Analysis Of Quality Of Life And Symptom Relief.
Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment

Advanced or Metastatic Breast Cancer,, or ER+ve Advanced or Metas Clinical Trial using AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

AstraZeneca - Recruiting 18 years or older.
- A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status..
AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 16 years to 50 years.
- A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome.
iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region..

Stage I Breast Carcinoma, or Stage II Breast Carcinoma Clinical Trial using intra-operative MRI

Dana-Farber Cancer Institute - Recruiting 18 years to 75 years.
- A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO).
intra-operative MRI

Metastatic Hepatocellular Carcinoma, or Advanced Liver Cancer Clinical Trial using Ascorbic Acid + Sorafenib; Sorafenib alone

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma.
Ascorbic Acid + Sorafenib; Sorafenib alone

Various Advanced Cancer Clinical Trial using BMS-986115

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors.
BMS-986115

Advanced NSCLC, or First Line Treatment Clinical Trial using Exercise Intervention; Care-Management-Phone-Calls

German Cancer Research Center - Recruiting 18 years or older.
- Physical Exercise Program in Lung Cancer Patients With Non-operable Disease Undergoing Palliative Treatment.
Exercise Intervention; Care-Management-Phone-Calls

Stage IV Pancreatic Cancer Clinical Trial using VXM01; Placebo

Vaximm GmbH - Recruiting 18 years or older.
- VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01.
VXM01; Placebo

Advanced Breast Cancer Clinical Trial

Dartmouth-Hitchcock Medical Center - Recruiting 18 years or older.
- Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer.

Cancer, Advanced Solid Tumors Clinical Trial using BBI503

Boston Biomedical, Inc - Recruiting 18 years or older.
- A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors.
BBI503

Cancer Clinical Trial using ARGX-111

arGEN-X BVBA - Recruiting 18 years or older.
- A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein..
ARGX-111

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase IIIb, Open-label Study of Erlotinib (Tarcevar) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE).
erlotinib [Tarceva]

Malignant Melanoma Clinical Trial using Observation

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- The High-Dose Aldesleukin (IL-2) 'SELECT' Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma.
Observation

Advanced Cancers Clinical Trial using Hydroxychloroquine; Sirolimus; Vorinostat

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies.
Hydroxychloroquine; Sirolimus; Vorinostat

Squamous Cell Carcinoma of the Oral Cavity, or Squamous Cell Carc Clinical Trial using LI plus CIZ; Standard of Care (SOC); LI + SOC

CEL-SCI Corporation - Recruiting 18 years or older.
- Phase III Study of LI [Multikiner] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only.
LI plus CIZ; Standard of Care (SOC); LI + SOC

Pancreatic Cancer Clinical Trial using TH-302; Nab-paclitaxel; Gemcitabine

EMD Serono - Recruiting 18 years or older.
- An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma.
TH-302; Nab-paclitaxel; Gemcitabine

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer.
RAD001

Head and Neck Cancer Clinical Trial using 6 weeks of Radiotherapy; 5 weeks of Radiotherapy

University of California, Davis - Recruiting 18 years or older.
- Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV).
6 weeks of Radiotherapy; 5 weeks of Radiotherapy

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using nanosomal docetaxel lipid suspension; pharmacological study

USC/Norris Comprehensive Cancer Center - Recruiting 18 years to 64 years.
- An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors.
nanosomal docetaxel lipid suspension; pharmacological study

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

Ovarian Cancer Clinical Trial using Palliative Performance Scale version 2 (PPSv2); McCorkle Symptom Distress Scale (SDS); Geriatric Assessment; Medical Records Abstraction

UNC Lineberger Comprehensive Cancer Center - Recruiting 65 years or older.
- Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer.
Palliative Performance Scale version 2 (PPSv2); McCorkle Symptom Distress Scale (SDS); Geriatric Assessment; Medical Records Abstraction

Metastatic Pancreatic Cancer, or Pancreatic Cancer Clinical Trial using Folfirinox

Yale University - Recruiting 18 years or older.
- Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer.
Folfirinox

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Cancer Clinical Trial using Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors.
Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

CANCER, NOS Clinical Trial using Lirilumab; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors.
Lirilumab; Ipilimumab

Neoplasm Malignant Clinical Trial using SAR405838; Pimasertib

Sanofi - Recruiting 18 years or older.
- A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer.
SAR405838; Pimasertib

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Advanced or Metastatic Solid Tumors, or Advanced or Metastatic Br Clinical Trial using Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

University of Utah - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of t Clinical Trial using Ipilimumab; Best Supportive care (BSC)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer.
Ipilimumab; Best Supportive care (BSC)

Head and Neck Cancer Clinical Trial using Everolimus (RAD 001) or placebo

University of Chicago - Recruiting 18 years or older.
- Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN).
Everolimus (RAD 001) or placebo

Head and Neck Cancer Clinical Trial using Everolimus escalating dose; Everolimus or Placebo

University of Chicago - Recruiting 18 years to 89 years.
- Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Everolimus escalating dose; Everolimus or Placebo

Cancer of the Cervix, or Cervical Neoplasms Clinical Trial using Boost radiation

Duke University - Recruiting 18 years or older.
- Integrated Dose Escalation for Advanced, Localized Cervical Cancer (The IDEAL - Cervix Trial).
Boost radiation

CANCER,NOS Clinical Trial using Lirilumab; Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Patients With Advanced Solid Tumors.
Lirilumab; Nivolumab

Non-Small Cell Lung Cancer Clinical Trial using Custirsen + Docetaxel; Docetaxel

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer.
Custirsen + Docetaxel; Docetaxel

Prostate Cancer Clinical Trial using APC-100

Adamis Pharmaceuticals Corporation - Recruiting 18 years or older.
- Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer.
APC-100

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; erlotinib

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy.
afatinib; erlotinib

Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourin Clinical Trial using IGF-Methotrexate

University of Illinois at Chicago - Recruiting 18 years or older.
- STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R.
IGF-Methotrexate

Colorectal Cancer, or Advanced Colorectal Cancer Clinical Trial using Tumour markers testing

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer 'SPECTAcolor'.
Tumour markers testing

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

Gastric Cancer Clinical Trial

Hospital Miguel Servet - Recruiting 18 years or older.
- Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients: A Prospective Observational Study ('EXO-PPP Study').

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Liver Cancer Clinical Trial using onartuzumab; sorafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
onartuzumab; sorafenib

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label Study of Erlotinib (Tarcevar) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
erlotinib [Tarceva]

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Ovarian Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OBSERVATIONAL STUDY OF AVASTINr (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER.

Metastatic Solid Tumors Clinical Trial using MLN1117

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease.
MLN1117

Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squam Clinical Trial using OPB-111001

Otsuka Novel Products GmbH - Recruiting 18 years or older.
- A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment.
OPB-111001

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesop Clinical Trial using oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia.
oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Advanced Solid Tumor Diseases Clinical Trial using Individual Meaning-Centered Psychotherapy (IMCP); standard Individual Supportive Psychotherapy (ISP); enhanced usual care (EUC)

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- A Randomized Controlled Trial of Individual Psychosocial Interventions for Cancer Patients.
Individual Meaning-Centered Psychotherapy (IMCP); standard Individual Supportive Psychotherapy (ISP); enhanced usual care (EUC)

Neoplasm Malignant Clinical Trial using SAR405838

Sanofi - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer.
SAR405838

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Ca Clinical Trial using docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

Thyroid Neoplasms Clinical Trial using Ponatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer.
Ponatinib

Pancreatic Cancer Clinical Trial using LY2495655; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy.
LY2495655; Placebo

Neoplasms, Neoplasm Metastasis, or Lymphoma Clinical Trial using LY3039478

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer.
LY3039478

Cervical Cancer Clinical Trial using Propranolol; Diary; Relaxation Audio Recording; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Effect of a Beta Andrenergic Blockade Combined With Relaxation/Guided Imagery Audio Intervention on Symptom Distress in Women With Advanced, Recurrent Incurable Cervical Cancer - Feasibility Study.
Propranolol; Diary; Relaxation Audio Recording; Questionnaires

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Cancer Clinical Trial using LY2801653; Cetuximab; Cisplatin

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY2801653 in Patients With Advanced Cancer.
LY2801653; Cetuximab; Cisplatin

Squamous Non-small Cell Lung Cancer Clinical Trial using Necitumumab; Gemcitabine; Cisplatin

Eli Lilly and Company - Recruiting 20 years or older.
- An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
Necitumumab; Gemcitabine; Cisplatin

Pancreatic Cancer Clinical Trial using Kanglaite Injection plus gemcitabine; Gemcitabine

KangLaiTe USA - Recruiting 18 years or older.
- A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Kanglaite Injection plus gemcitabine; Gemcitabine

Advanced, Metastatic Breast Cancer Clinical Trial using LEE011; Letrozole; Letrozole Placebo

Novartis - Recruiting N/A or older.
- A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
LEE011; Letrozole; Letrozole Placebo

Advanced Cancer Clinical Trial using SENS model

University Hospital Inselspital, Berne - Recruiting 18 years or older.
- A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial).
SENS model

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, or Metastatic Clinical Trial using Cabazitaxel-XRP6258

University of Alabama at Birmingham - Recruiting 19 years or older.
- Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.
Cabazitaxel-XRP6258

Advanced Cancers Clinical Trial using Litebook; Melatonin; Methylphenidate; Placebo; Counseling Sessions; Questionnaires; Study Diaries

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer.
Litebook; Melatonin; Methylphenidate; Placebo; Counseling Sessions; Questionnaires; Study Diaries

NSCLC, Non-small Cell Lung Cancer, or Lung Cancer Clinical Trial using MEDI4736; Tremelimumab

MedImmune LLC - Recruiting 18 years or older.
- A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer.
MEDI4736; Tremelimumab

Non-small Cell Lung Cancer Metastatic Clinical Trial using Erlotinib

National Guard Health Affairs - Recruiting 18 years or older.
- Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME).
Erlotinib

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status.
6,8-bis(benzylthio)octanoic acid

Gastrointestinal Cancers Clinical Trial using Capecitabine; Oxaliplatin; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater.
Capecitabine; Oxaliplatin; Bevacizumab

Advanced Cancers Clinical Trial using Temsirolimus; Metformin

M.D. Anderson Cancer Center - Recruiting 14 years or older.
- Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers.
Temsirolimus; Metformin

Colorectal Cancer Clinical Trial using Dacomitinib; PD-0325901; Irinotecan; Docetaxel; Capecitabine

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Advanced KRAS Mutation Positive Colorectal, Non-small Cell Lung and Pancreatic Cancer.
Dacomitinib; PD-0325901; Irinotecan; Docetaxel; Capecitabine

Rectal Cancer Clinical Trial using CRLX101; Capecitabine; Radiotherapy; Surgery

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase Ib/II Study of Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Locally Advanced Rectal Cancer.
CRLX101; Capecitabine; Radiotherapy; Surgery

Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers.
6,8-bis(benzylthio)octanoic acid

Gastric Cancer Clinical Trial using RAD001

Chinese University of Hong Kong - Recruiting 18 years or older.
- Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach.
RAD001

Advanced Cancer Clinical Trial using Survey

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System.
Survey

Pain Clinical Trial using Sativexr; Placebo (GA-0034)

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativexr in Relieving Persistent Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy..
Sativexr; Placebo (GA-0034)

Ovarian Cancer Clinical Trial using Paclitaxel + Carboplatin every 3 weeks; Carboplatin monotherapy every 3 weeks; Weekly Paclitaxel and Carboplatin

Hospices Civils de Lyon - Recruiting 70 years or older.
- EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer.
Paclitaxel + Carboplatin every 3 weeks; Carboplatin monotherapy every 3 weeks; Weekly Paclitaxel and Carboplatin

Advanced Gastric Cancer, or Esophagogastric Junction Cancer Clinical Trial using Paclitaxel; RAD001

Krankenhaus Nordwest - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.
Paclitaxel; RAD001

Carcinoma, Hepatocellular Clinical Trial using PF-03446962; Best Supportive Care; Best supportive care

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Open Label Study To Evaluate The Efficacy, Safety, Pharmacodynamics, Pharmacokinetics Of The Anti-ALK-1 MAB PF-03446962 In Combination With Best Supportive Care VS. Best Supportive Care Alone In Adult Patients With Advanced Hepatocellular Carcinoma.
PF-03446962; Best Supportive Care; Best supportive care

Pain/Cancer, or Pain, Intractable Clinical Trial using (Resiniferatoxin)(RTX); Intrathecal Resiniferatoxin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer.
(Resiniferatoxin)(RTX); Intrathecal Resiniferatoxin

Pain, or Advanced Cancer Clinical Trial using Sativexr; Placebo (GA-0034)

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativexr Oromucosal Spray (Sativexr; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.
Sativexr; Placebo (GA-0034)

Colorectal Neoplasms, Colorectal Carcinoma, or Colorectal Tumors Clinical Trial using ISIS 183750; Irinotecan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer.
ISIS 183750; Irinotecan

Non-small Cell Lung Cancer Clinical Trial using Dacomitinib

Pfizer - Recruiting 18 years or older.
- Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC.
Dacomitinib

Gastric Cancer Clinical Trial using Cabazitaxel

Krankenhaus Nordwest - Recruiting 18 years or older.
- Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach.
Cabazitaxel

Advanced Gastric Cancer Clinical Trial using Docetaxel, Capecitabine, Cisplatin, Bevacizumab

Asan Medical Center - Recruiting 18 years to 70 years.
- A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer.
Docetaxel, Capecitabine, Cisplatin, Bevacizumab

Advanced Gastric Cancer Clinical Trial using Cisplatin, TS-1 and oxaliplatin

National University Hospital, Singapore - Recruiting 21 years or older.
- .
Cisplatin, TS-1 and oxaliplatin

Metastatic Colorectal Cancer Clinical Trial using BKM120; Panitumumab

NCIC Clinical Trials Group - Recruiting 18 years or older.
- Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer..
BKM120; Panitumumab

Endometrial Cancer Clinical Trial using Metformin; Letrozole; Everolimus

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma.
Metformin; Letrozole; Everolimus

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using PET/CT

National Cancer Institute, Naples - Recruiting 18 years or older.
- Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC).
PET/CT

Non-small Cell Lung Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastinr (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients.
Bevacizumab; Paclitaxel; Carboplatin

Metastatic or Recurrent Gastric Adenocarcinoma, or Her-2 Positive Clinical Trial using Herceptin+XELOX

Asan Medical Center - Recruiting 20 years or older.
- A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.
Herceptin+XELOX

Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cance Clinical Trial using FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Southwest Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.
FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Rectal Cancer Clinical Trial using conventional ELAPE; Individual ELAPE

Beijing Chao Yang Hospital - Recruiting 18 years to 80 years.
- Randomized Clinical Trial of Conventional Versus Individual Extralevator Abdominoperineal Excision for Locally Advanced Lower Rectal Cancer.
conventional ELAPE; Individual ELAPE

Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, or Esophag Clinical Trial using GS-5745 monotherapy and in combination with chemotherapy

Gilead Sciences - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors.
GS-5745 monotherapy and in combination with chemotherapy

Non-Small Cell Lung Cancer Clinical Trial using LDK378; pemetrexed; docetaxel

Novartis - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib.
LDK378; pemetrexed; docetaxel

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using recombinant hsp110-gp100 chaperone complex vaccine

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma.
recombinant hsp110-gp100 chaperone complex vaccine

Patients With Unresectable Nonmetastatic Locally Advanced Pancrea Clinical Trial using Gemcitabine 1000 mg/m2; Oxaliplatin 100 mg/m2; Hypofractionated radiotherapy (35 Gy in 7 fractions)

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori - Recruiting 18 years to 75 years.
- Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer..
Gemcitabine 1000 mg/m2; Oxaliplatin 100 mg/m2; Hypofractionated radiotherapy (35 Gy in 7 fractions)

Solid Tumors, or Non-small Cell Lung Cancer Clinical Trial using oral 5-azacitidine in combination with romidepsin

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer.
oral 5-azacitidine in combination with romidepsin

Non-small Cell Lung Cancer Clinical Trial using MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Merck KGaA - Recruiting 18 years or older.
- A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib.
MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Non-HPV Locally Advanced Head and Neck Cancer Clinical Trial using intensity modulated radiation therapy; Cisplatin; placebo; Lapatinib

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerbr) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation.
intensity modulated radiation therapy; Cisplatin; placebo; Lapatinib

Liver Cancer, or Advanced Cancer Clinical Trial using Irinotecan; Bevacizumab; Oxaliplatin; Cetuximab

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver.
Irinotecan; Bevacizumab; Oxaliplatin; Cetuximab

Lung Cancer Clinical Trial using Carboplatin; Pemetrexed; Bevacizumab; Cetuximab; Cixutumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting.
Carboplatin; Pemetrexed; Bevacizumab; Cetuximab; Cixutumumab

Lung Cancer Clinical Trial using bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer.
bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

Rectal Cancer Clinical Trial using Sorafenib; 5-Fluorouracil (5-FU); Radiation

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
Sorafenib; 5-Fluorouracil (5-FU); Radiation